Changes

Jump to: navigation, search

Erdafitinib (Balversa)

1 byte added, 15:05, 12 May 2019
m
no edit summary
==General information==
Class/mechanism: Tyrosine kinase inhibitor. Erdafitinib inhibits multiple receptor tyrosine kinases (RTKs), including fibroblast growth factor receptors (FGFR) FGFR1, FGFR2, FGFR3, FGFR4, as well as RET, CSF1R, PDGFRA, PDGFRB, FLT4, KIT, and VEGFR2. Erdafitinib inhibits FGFR-related phosphorylation and signal transduction, resulting in inhibition and tumor cell death in FGFR-overexpressing tumor cells.<ref name="insert">[http://www.janssenlabels.com/package-insert/product-monograph/prescribing-information/BALVERSA-pi.pdf Erdafitinib (Balversa) package insert]</ref><ref>[[Media:Erdafitinib.pdf| Erdafitinib (Balversa) package insert (locally hosted backup)]]</ref><ref>[https://www.balversa.com/ Balversa manufacturer's website]</ref>
<br>Route: PO
<br>Extravasation: n/a
LookupUsers, editors, emailconfirmed
3,827
edits

Navigation menu